Table 3.
Promoter | Gender | Age at surgery | Mutation | Tumor type | Metastatic disease | Outcome | CIMP |
---|---|---|---|---|---|---|---|
Series A | |||||||
Mean Z-score | NS | NS | <0.007 | <0.0002 | <0.0004 | 0.01 | <0.005 |
DCR2 | NS | NS | <0.01 | 0.01 | <0.02 | NS | <0.005 |
CDH1 | NS | NS | NS | NS | <0.04 | NS | NS |
NORE1A | NS | NS | NS | 0.002 | <0.006 | 0.01 | 0.01 |
P16 | 0.04 | NS | 0.005 | 0.001 | <0.05 | NS | <0.005 |
RARB | NS | NS | 0.02 | <0.005 | NS | NS | <0.05 |
RASSF1A | NS | NS | 0.005 | <0.008 | 0.002 | 0.009 | 0.01 |
LINE1 | 0.003 | <0.05 | NS | NS | NS | NS | NS |
Series A+B | |||||||
Mean Z-score | NS | NS | 0.0002 | <0.00001 | 0.0006 | <0.0009 | <0.000001 |
DCR2 | <0.002 | NS | 0.0003 | <0.0002 | 0.01 | <0.02 | <0.000001 |
CDH1 | NS | NS | <0.01 | 0.03 | 0.04 | 0.03 | NS |
NORE1A | NS | NS | NS | 0.01 | 0.005 | <0.04 | 0.02 |
P16 | NS | NS | 0.0002 | 0.00002 | 0.002 | <0.02 | <0.000001 |
RARB | NS | NS | 0.003 | <0.008 | <0.05 | NS | <0.0003 |
RASSF1A | NS | NS | 0.0002 | 0.0004 | <0.0004 | <0.0008 | <0.000001 |
LINE1 | <0.002 | NS | NS | NS | NS | NS | NS |
NS, not significant.